Global Biologics Clinical Manufacturing CDMO Service 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06253867

Publication Date:

June 20, 2025

Pages:

129

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Biologics Clinical Manufacturing CDMO Service market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
United States market for Biologics Clinical Manufacturing CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Biologics Clinical Manufacturing CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Biologics Clinical Manufacturing CDMO Service is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Biologics Clinical Manufacturing CDMO Service players cover Thermo Fisher Scientific, Lonza, Intertek, Charles River Laboratories, Bio-Rad, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淏iologics Clinical Manufacturing CDMO Service Industry Forecast鈥� looks at past sales and reviews total world Biologics Clinical Manufacturing CDMO Service sales in 2024, providing a comprehensive analysis by region and market sector of projected Biologics Clinical Manufacturing CDMO Service sales for 2025 through 2031. With Biologics Clinical Manufacturing CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biologics Clinical Manufacturing CDMO Service industry.
This Insight Report provides a comprehensive analysis of the global Biologics Clinical Manufacturing CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biologics Clinical Manufacturing CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Biologics Clinical Manufacturing CDMO Service market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biologics Clinical Manufacturing CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biologics Clinical Manufacturing CDMO Service.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics Clinical Manufacturing CDMO Service market by product type, application, key players and key regions and countries.
Segmentation by Type:
Traditional API CDMO
Highly Potent API CDMO
Segmentation by Application:
Big Pharmaceutical Companies
Small and Medium Pharmaceutical Companies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Lonza
Intertek
Charles River Laboratories
Bio-Rad
Element
ProPharma
Ascendia
Minaris Regenerative Medicine
TriLink BioTechnologies
Oakwood Labs
PiramalPharma Solutions
Boehringer-Ingelheim
Wuxi Apptec
Pharmaron Beijing
Asymchem Laboratories (Tianjin)
Porton
SEQENS

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size (2020-2031)
2.1.2 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Biologics Clinical Manufacturing CDMO Service by Country/Region (2020, 2024 & 2031)
2.2 Biologics Clinical Manufacturing CDMO Service Segment by Type
2.2.1 Traditional API CDMO
2.2.2 Highly Potent API CDMO
2.3 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Type
2.3.1 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Biologics Clinical Manufacturing CDMO Service Segment by Application
2.4.1 Big Pharmaceutical Companies
2.4.2 Small and Medium Pharmaceutical Companies
2.5 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Application
2.5.1 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Player
3.1 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Biologics Clinical Manufacturing CDMO Service Revenue by Player (2020-2025)
3.1.2 Global Biologics Clinical Manufacturing CDMO Service Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Biologics Clinical Manufacturing CDMO Service Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Biologics Clinical Manufacturing CDMO Service by Region
4.1 Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Region (2020-2025)
4.2 Global Biologics Clinical Manufacturing CDMO Service Annual Revenue by Country/Region (2020-2025)
4.3 Americas Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size Growth (2020-2025)
4.4 APAC Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size Growth (2020-2025)
4.5 Europe Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Country (2020-2025)
5.2 Americas Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Type (2020-2025)
5.3 Americas Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Region (2020-2025)
6.2 APAC Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Type (2020-2025)
6.3 APAC Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Country (2020-2025)
7.2 Europe Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Type (2020-2025)
7.3 Europe Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Biologics Clinical Manufacturing CDMO Service by Region (2020-2025)
8.2 Middle East & Africa Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Biologics Clinical Manufacturing CDMO Service 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Biologics Clinical Manufacturing CDMO Service 麻豆原创 Forecast
10.1 Global Biologics Clinical Manufacturing CDMO Service Forecast by Region (2026-2031)
10.1.1 Global Biologics Clinical Manufacturing CDMO Service Forecast by Region (2026-2031)
10.1.2 Americas Biologics Clinical Manufacturing CDMO Service Forecast
10.1.3 APAC Biologics Clinical Manufacturing CDMO Service Forecast
10.1.4 Europe Biologics Clinical Manufacturing CDMO Service Forecast
10.1.5 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Forecast
10.2 Americas Biologics Clinical Manufacturing CDMO Service Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.2.2 Canada 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.2.3 Mexico 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.2.4 Brazil 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.3 APAC Biologics Clinical Manufacturing CDMO Service Forecast by Region (2026-2031)
10.3.1 China Biologics Clinical Manufacturing CDMO Service 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.3.3 Korea 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.3.4 Southeast Asia 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.3.5 India 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.3.6 Australia 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.4 Europe Biologics Clinical Manufacturing CDMO Service Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.4.2 France 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.4.3 UK 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.4.4 Italy 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.4.5 Russia 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.5 Middle East & Africa Biologics Clinical Manufacturing CDMO Service Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.5.2 South Africa 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.5.3 Israel 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.5.4 Turkey 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
10.6 Global Biologics Clinical Manufacturing CDMO Service Forecast by Type (2026-2031)
10.7 Global Biologics Clinical Manufacturing CDMO Service Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Biologics Clinical Manufacturing CDMO Service Forecast
11 Key Players Analysis
11.1 Thermo Fisher Scientific
11.1.1 Thermo Fisher Scientific Company Information
11.1.2 Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Product Offered
11.1.3 Thermo Fisher Scientific Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Thermo Fisher Scientific Main Business Overview
11.1.5 Thermo Fisher Scientific Latest Developments
11.2 Lonza
11.2.1 Lonza Company Information
11.2.2 Lonza Biologics Clinical Manufacturing CDMO Service Product Offered
11.2.3 Lonza Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Lonza Main Business Overview
11.2.5 Lonza Latest Developments
11.3 Intertek
11.3.1 Intertek Company Information
11.3.2 Intertek Biologics Clinical Manufacturing CDMO Service Product Offered
11.3.3 Intertek Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Intertek Main Business Overview
11.3.5 Intertek Latest Developments
11.4 Charles River Laboratories
11.4.1 Charles River Laboratories Company Information
11.4.2 Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Product Offered
11.4.3 Charles River Laboratories Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Charles River Laboratories Main Business Overview
11.4.5 Charles River Laboratories Latest Developments
11.5 Bio-Rad
11.5.1 Bio-Rad Company Information
11.5.2 Bio-Rad Biologics Clinical Manufacturing CDMO Service Product Offered
11.5.3 Bio-Rad Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Bio-Rad Main Business Overview
11.5.5 Bio-Rad Latest Developments
11.6 Element
11.6.1 Element Company Information
11.6.2 Element Biologics Clinical Manufacturing CDMO Service Product Offered
11.6.3 Element Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Element Main Business Overview
11.6.5 Element Latest Developments
11.7 ProPharma
11.7.1 ProPharma Company Information
11.7.2 ProPharma Biologics Clinical Manufacturing CDMO Service Product Offered
11.7.3 ProPharma Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 ProPharma Main Business Overview
11.7.5 ProPharma Latest Developments
11.8 Ascendia
11.8.1 Ascendia Company Information
11.8.2 Ascendia Biologics Clinical Manufacturing CDMO Service Product Offered
11.8.3 Ascendia Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Ascendia Main Business Overview
11.8.5 Ascendia Latest Developments
11.9 Minaris Regenerative Medicine
11.9.1 Minaris Regenerative Medicine Company Information
11.9.2 Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Product Offered
11.9.3 Minaris Regenerative Medicine Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Minaris Regenerative Medicine Main Business Overview
11.9.5 Minaris Regenerative Medicine Latest Developments
11.10 TriLink BioTechnologies
11.10.1 TriLink BioTechnologies Company Information
11.10.2 TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Product Offered
11.10.3 TriLink BioTechnologies Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 TriLink BioTechnologies Main Business Overview
11.10.5 TriLink BioTechnologies Latest Developments
11.11 Oakwood Labs
11.11.1 Oakwood Labs Company Information
11.11.2 Oakwood Labs Biologics Clinical Manufacturing CDMO Service Product Offered
11.11.3 Oakwood Labs Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Oakwood Labs Main Business Overview
11.11.5 Oakwood Labs Latest Developments
11.12 PiramalPharma Solutions
11.12.1 PiramalPharma Solutions Company Information
11.12.2 PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Product Offered
11.12.3 PiramalPharma Solutions Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 PiramalPharma Solutions Main Business Overview
11.12.5 PiramalPharma Solutions Latest Developments
11.13 Boehringer-Ingelheim
11.13.1 Boehringer-Ingelheim Company Information
11.13.2 Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Product Offered
11.13.3 Boehringer-Ingelheim Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Boehringer-Ingelheim Main Business Overview
11.13.5 Boehringer-Ingelheim Latest Developments
11.14 Wuxi Apptec
11.14.1 Wuxi Apptec Company Information
11.14.2 Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Product Offered
11.14.3 Wuxi Apptec Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Wuxi Apptec Main Business Overview
11.14.5 Wuxi Apptec Latest Developments
11.15 Pharmaron Beijing
11.15.1 Pharmaron Beijing Company Information
11.15.2 Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Product Offered
11.15.3 Pharmaron Beijing Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Pharmaron Beijing Main Business Overview
11.15.5 Pharmaron Beijing Latest Developments
11.16 Asymchem Laboratories (Tianjin)
11.16.1 Asymchem Laboratories (Tianjin) Company Information
11.16.2 Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Product Offered
11.16.3 Asymchem Laboratories (Tianjin) Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Asymchem Laboratories (Tianjin) Main Business Overview
11.16.5 Asymchem Laboratories (Tianjin) Latest Developments
11.17 Porton
11.17.1 Porton Company Information
11.17.2 Porton Biologics Clinical Manufacturing CDMO Service Product Offered
11.17.3 Porton Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Porton Main Business Overview
11.17.5 Porton Latest Developments
11.18 SEQENS
11.18.1 SEQENS Company Information
11.18.2 SEQENS Biologics Clinical Manufacturing CDMO Service Product Offered
11.18.3 SEQENS Biologics Clinical Manufacturing CDMO Service Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 SEQENS Main Business Overview
11.18.5 SEQENS Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.